TimesSquare Capital Management LLC grew its holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.0% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 665,100 shares of the medical research company’s stock after acquiring an additional 43,450 shares during the quarter. Bio-Rad Laboratories accounts for 1.0% of TimesSquare Capital Management LLC’s portfolio, making the stock its 13th largest holding. TimesSquare Capital Management LLC owned approximately 2.24% of Bio-Rad Laboratories worth $147,799,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Sivik Global Healthcare LLC acquired a new position in shares of Bio-Rad Laboratories in the third quarter valued at $2,222,000. Pacer Advisors Inc. raised its stake in Bio-Rad Laboratories by 14.1% during the third quarter. Pacer Advisors Inc. now owns 3,771 shares of the medical research company’s stock worth $838,000 after acquiring an additional 465 shares in the last quarter. Macquarie Group Ltd. bought a new position in Bio-Rad Laboratories in the third quarter valued at about $255,000. Timber Hill LLC bought a new position in Bio-Rad Laboratories in the third quarter valued at about $214,000. Finally, Advisors Asset Management Inc. boosted its holdings in Bio-Rad Laboratories by 6.9% in the third quarter. Advisors Asset Management Inc. now owns 19,051 shares of the medical research company’s stock valued at $4,234,000 after acquiring an additional 1,230 shares during the last quarter. 62.76% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was stolen and reposted in violation of United States & international copyright & trademark law. The legal version of this news story can be viewed at https://www.watchlistnews.com/bio-rad-laboratories-inc-bio-holdings-raised-by-timessquare-capital-management-llc/1722020.html.

In other Bio-Rad Laboratories news, EVP Giovanni Magni sold 2,400 shares of the firm’s stock in a transaction dated Tuesday, November 14th. The stock was sold at an average price of $253.01, for a total transaction of $607,224.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at $2,340,595.51. The sale was disclosed in a document filed with the SEC, which is available through this link. 28.29% of the stock is currently owned by company insiders.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) traded up $3.01 on Thursday, reaching $258.69. The company’s stock had a trading volume of 119,700 shares, compared to its average volume of 180,902. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.77 and a current ratio of 4.06. Bio-Rad Laboratories, Inc. has a 12-month low of $169.19 and a 12-month high of $268.40. The company has a market capitalization of $7,609.80, a PE ratio of 81.17, a P/E/G ratio of 3.86 and a beta of 0.88.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, November 2nd. The medical research company reported $0.91 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.37. Bio-Rad Laboratories had a return on equity of 3.44% and a net margin of 1.15%. The firm had revenue of $535.00 million for the quarter, compared to analysts’ expectations of $507.99 million. During the same quarter last year, the business earned $0.62 earnings per share. The company’s revenue was up 5.2% compared to the same quarter last year. equities analysts expect that Bio-Rad Laboratories, Inc. will post 2.65 earnings per share for the current fiscal year.

BIO has been the topic of several recent research reports. TheStreet cut Bio-Rad Laboratories from a “b” rating to a “c+” rating in a report on Thursday, August 3rd. Zacks Investment Research cut Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $255.00 price target on shares of Bio-Rad Laboratories in a report on Monday, September 18th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Bio-Rad Laboratories presently has an average rating of “Buy” and an average target price of $260.00.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.